Anti-Mucin 1 (MUC1) Antibody Pipeline Insights, 2018 Report - ResearchAndMarkets.com

August 27, 2018

DUBLIN--(BUSINESS WIRE)--Aug 27, 2018--The “Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Mucin 1 (MUC1) Antibody development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Anti-Mucin 1 (MUC1) Antibody - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Anti-Mucin 1 (MUC1) Antibody - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Anti-Mucin 1 (MUC1) Antibody Pipeline Products in Clinical Stages

6. Anti-Mucin 1 (MUC1) Antibody Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned

Akshaya Bio Inc Bavarian Nordic A/S Boehringer Ingelheim GmbH Etubics Corp GeoVax Labs Inc Merck KGaA Minerva Biotechnologies Corp Transgene SA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zfrcs2/antimucin_1?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180827005540/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Breast Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/27/2018 02:57 PM/DISC: 08/27/2018 02:57 PM


Update hourly